Bioextrax ABOMXSTO: BIOEX

BIOEX: Sales growth and improved margins signal progress in Bioextrax's commercialization

· Issued by Bioextrax AB

Net sales increased to 79 tkr in Q1 2025, with operating losses narrowing and key customer projects advancing toward commercialization. Liquidity is secured for the next 12 months following a rights issue.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Bioextrax AB on 6ix

Story so far

Earlier from Bioextrax

Later from Bioextrax

All Bioextrax news releases